The concern of generic challenges has long loomed over copyright’s blockbuster drug, PDE5 Inhibitor, raising questions about the outlook of related pharmaceutical stakes. While first periods saw significant returns, the patent expiration has created the door for less expensive alternatives, potentially reducing revenue and presenting a genuine ri